Versantis is set to receive nearly $508,753 (Sfr475,000) from Swiss national innovation agency Innosuisse for the development of a point-of-care (POC) device to monitor blood ammonia in liver disease patients.
The company plans to enlist the Zurich University of Applied Sciences School of Engineering and develop a prototype POC device, TS-01, using a polymersome-based ammonia quantification method.
TS-01 is designed for the measurement of ammonia in blood at home, mainly for hepatic encephalopathy (HE).
